Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932185 | 0.88 | PRMT1 (0.57) | PRMT1DRD2DRD4DRD3LMNA | |
| SCHEMBL9955066 | 0.84 | PRMT1 (0.60) | PRMT1DRD2DRD4DRD3LMNA | |
| SCHEMBL931132 | 0.83 | HTR1A (0.54) | DRD2HTR1A | |
| SCHEMBL932001 | 0.81 | — | — | |
| SCHEMBL931464 | 0.81 | GRIN2B (0.67) | DRD2HTR1ALMNAALDH1A1MAPK1 | |
| SCHEMBL6773949 | 0.80 | — | — | |
| SCHEMBL28795918 | 0.80 | PRMT1 (0.55) | PRMT1DRD3 | |
| SCHEMBL4249962 | 0.79 | ACHE (0.55) | PRMT1LMNAALDH1A1 | |
| SCHEMBL9230826 | 0.78 | DRD2 (0.55) | DRD2HTR1ADRD4DRD3BACE1 | |
| SCHEMBL8545092 | 0.77 | PRMT1 (0.57) | PRMT1DRD2HTR1ADRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-2448934-B1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES | ASTRAZENECA AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| CN-102482264-A | 2-carbamoyl-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| EP-2448934-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | AstraZeneca AB (SE) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | C1R, HTR4, HTR2C | PRMT1 412/4885DRD2 82/4885HTR1A 48/4885 |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | C1R, CBR1, HTR2C | PRMT1 452/4885DRD2 71/4885HTR1A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.